Trade Indaptus Therapeutics, Inc. - INDP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 1.25-4.25 |
| Average Volume (10 days) | 6,820.00 |
| Average Volume (3 months) | 194.86K |
| Market Cap | 14.11M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 8.26M |
| Revenue | N/A |
| EPS | -1.68 |
| Dividend (Yield %) | N/A |
| Beta | 1.18 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Indaptus Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | |||||
| Total Operating Expense | 7.72911 | 13.829 | 47.109 | 43.328 | 29.439 |
| Selling/General/Admin. Expenses, Total | 5.20596 | 7.089 | 8.287 | 7.926 | 5.144 |
| Research & Development | 2.52315 | 6.74 | 26.659 | 35.402 | 24.295 |
| Depreciation / Amortization | |||||
| Interest Expense (Income) - Net Operating | |||||
| Other Operating Expenses, Total | 0 | -1.5 | |||
| Operating Income | -7.72911 | -13.829 | -47.109 | -43.328 | -29.439 |
| Interest Income (Expense), Net Non-Operating | 0.01772 | -0.165 | 0.163 | -0.089 | 0.576 |
| Net Income Before Taxes | -7.71139 | -14.004 | -46.961 | -43.44 | -28.88 |
| Net Income After Taxes | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Net Income Before Extra. Items | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Net Income | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Income Available to Common Excl. Extra. Items | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Income Available to Common Incl. Extra. Items | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Diluted Net Income | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Diluted Weighted Average Shares | 4.0906 | 0.86525 | 0.4222 | 0.38991 | 0.22075 |
| Diluted EPS Excluding Extraordinary Items | -1.88515 | -16.3282 | -112.74 | -111.674 | -130.958 |
| Diluted Normalized EPS | -1.88515 | -16.3282 | -91.7055 | -111.674 | -130.958 |
| Other, Net | -0.01 | -0.015 | -0.023 | -0.017 | |
| Unusual Expense (Income) | 0 | 13.663 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 3.40207 | 3.2185 | 3.36799 | 1.14262 | 0.61398 |
| Selling/General/Admin. Expenses, Total | 2.10498 | 2.27386 | 2.67032 | 0.26178 | 0.12425 |
| Research & Development | 1.2971 | 0.94464 | 0.69767 | 0.88084 | 0.48972 |
| Operating Income | -3.40207 | -3.2185 | -3.36799 | -1.14262 | -0.61398 |
| Other, Net | 0.03692 | 0.00155 | |||
| Net Income Before Taxes | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Net Income After Taxes | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Net Income Before Extra. Items | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Net Income | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Income Available to Common Excl. Extra. Items | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Income Available to Common Incl. Extra. Items | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Diluted Net Income | -3.36515 | -3.21632 | -3.36716 | -1.1279 | -0.61242 |
| Diluted Weighted Average Shares | 8.2586 | 8.28409 | 4.18074 | 3.43676 | 1.94467 |
| Diluted EPS Excluding Extraordinary Items | -0.40747 | -0.38825 | -0.8054 | -0.32819 | -0.31492 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.40747 | -0.38825 | -0.8054 | -0.32819 | -0.31492 |
| Interest Income (Expense), Net Non-Operating | 0.00217 | 0.00083 | 0.01472 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 40.3872 | 14.968 | 13.745 | 43.565 | 56.343 |
| Cash and Short Term Investments | 39.1322 | 14.671 | 10.062 | 40.579 | 55.218 |
| Cash & Equivalents | 39.1322 | 14.671 | 9.292 | 39.246 | 53.393 |
| Short Term Investments | 0.77 | 1.333 | 1.825 | ||
| Total Receivables, Net | 0.085 | 3.486 | 2.031 | 0.478 | |
| Accounts Receivable - Trade, Net | 0.085 | 3.486 | 2.031 | 0.478 | |
| Other Current Assets, Total | 0.1484 | ||||
| Total Assets | 40.5766 | 20.896 | 21.28 | 61.51 | 64.549 |
| Property/Plant/Equipment, Total - Net | 0.17289 | 2.211 | 3.818 | 12.233 | 8.206 |
| Total Current Liabilities | 4.60414 | 5.334 | 8.342 | 7.656 | 5.747 |
| Payable/Accrued | 4.50768 | 0.368 | 3.507 | 2.849 | 1.854 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.37 | 4.835 | 0.02 | 0.033 | |
| Total Liabilities | 4.677 | 6.363 | 9.745 | 7.965 | 5.747 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.07286 | 1.029 | 1.403 | 0.309 | 0 |
| Total Equity | 35.8996 | 14.533 | 11.535 | 53.545 | 58.802 |
| Common Stock | 0.08259 | 0.727 | 0.727 | 0.727 | 0.727 |
| Additional Paid-In Capital | 51.4879 | 217.357 | 200.231 | 194.642 | 156.356 |
| Retained Earnings (Accumulated Deficit) | -15.6709 | -203.551 | -189.423 | -141.824 | -98.281 |
| Other Equity, Total | |||||
| Total Liabilities & Shareholders’ Equity | 40.5766 | 20.896 | 21.28 | 61.51 | 64.549 |
| Total Common Shares Outstanding | 8.2586 | 1.08032 | 0.44865 | 0.41541 | 0.32595 |
| Prepaid Expenses | 1.10665 | 0.212 | 0.197 | 0.955 | 0.647 |
| Property/Plant/Equipment, Total - Gross | 10.61 | 11.014 | 18.575 | 13.689 | |
| Accumulated Depreciation, Total | -8.399 | -7.196 | -6.342 | -5.483 | |
| Other Long Term Assets, Total | 0.01648 | 3.717 | 3.717 | 5.712 | 0 |
| Accrued Expenses | 0.09647 | 0.596 | 4.787 | 3.86 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 36.9197 | 40.3872 | 43.8549 | 18.792 | 12.159 |
| Cash and Short Term Investments | 36.1778 | 39.1322 | 41.8572 | 16.991 | 10.135 |
| Cash & Equivalents | 33.2163 | 39.1322 | 41.8572 | 16.991 | 10.135 |
| Prepaid Expenses | 0.74195 | 1.10665 | 1.39767 | 0.801 | 1.024 |
| Other Current Assets, Total | 0 | 0.1484 | 0.6 | 1 | 1 |
| Total Assets | 37.0866 | 40.5766 | 43.8592 | 20.092 | 17.43 |
| Property/Plant/Equipment, Total - Net | 0.15037 | 0.17289 | 0.00434 | 0 | 1.554 |
| Other Long Term Assets, Total | 0.01648 | 0.01648 | 1.3 | 3.717 | |
| Total Current Liabilities | 3.67966 | 4.60414 | 5.78018 | 5.44 | 5.203 |
| Payable/Accrued | 0.40032 | 4.50768 | 5.78018 | 0.397 | 0.183 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 5.043 | 5.02 | |||
| Total Liabilities | 3.73017 | 4.677 | 5.78018 | 6.156 | 6.086 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.05052 | 0.07286 | 0.716 | 0.883 | |
| Total Equity | 33.3564 | 35.8996 | 38.079 | 13.936 | 11.344 |
| Common Stock | 0.08259 | 0.08259 | 0.08133 | 0.727 | 0.727 |
| Additional Paid-In Capital | 52.3191 | 51.4879 | 50.4523 | 228.421 | 218.397 |
| Retained Earnings (Accumulated Deficit) | -19.036 | -15.6709 | -12.4546 | -215.212 | -207.78 |
| Total Liabilities & Shareholders’ Equity | 37.0866 | 40.5766 | 43.8592 | 20.092 | 17.43 |
| Total Common Shares Outstanding | 8.2586 | 8.2586 | 8.13324 | 1.85874 | 1.12565 |
| Accrued Expenses | 0.44466 | 0.09647 | |||
| Short Term Investments | 2.96146 | ||||
| Accounts Payable | 2.83468 | ||||
| Other Equity, Total | -0.00922 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
| Cash From Operating Activities | -11.2905 | -11.511 | -29.045 | -39.076 | -22.132 |
| Cash From Operating Activities | 0.0014 | 1.203 | 0.854 | 0.859 | 0.829 |
| Non-Cash Items | 1.49378 | 1.001 | 17.192 | 4.25 | 0.858 |
| Changes in Working Capital | -5.07433 | 0.413 | 0.508 | -0.642 | 5.09 |
| Cash From Investing Activities | 0.44775 | 0.75 | -3.21 | -9.301 | -4.747 |
| Capital Expenditures | -0.00385 | -0.022 | -0.921 | -4.667 | -5.001 |
| Other Investing Cash Flow Items, Total | 0.4516 | 0.772 | -2.289 | -4.634 | 0.254 |
| Cash From Financing Activities | 48.3375 | 15.978 | 2.368 | 35.059 | 63.707 |
| Issuance (Retirement) of Stock, Net | 27.6565 | 15.907 | 2.368 | 35.059 | 63.707 |
| Foreign Exchange Effects | 0.162 | -0.067 | -0.829 | 0.127 | |
| Net Change in Cash | 37.4947 | 5.379 | -29.954 | -14.147 | 36.955 |
| Cash Taxes Paid | 0.0008 | 0.009 | 0.075 | 0.096 | 0 |
| Financing Cash Flow Items | 20.681 | 0.071 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.36515 | -7.71139 | -4.49506 | -11.661 | -0.61242 |
| Cash From Operating Activities | -3.11773 | -11.2905 | -7.75082 | -7.397 | -0.82558 |
| Cash From Operating Activities | 0.00053 | 0.0014 | 0.00087 | 1.178 | 0.00021 |
| Non-Cash Items | 0.80703 | 1.49378 | 0.83646 | 3.493 | 0.02045 |
| Cash Taxes Paid | 0 | 0.0008 | 0.0008 | 0.01 | 0.0008 |
| Changes in Working Capital | -0.56014 | -5.07433 | -4.09308 | -0.407 | -0.23382 |
| Cash From Investing Activities | -2.79813 | 0.44775 | -0.00385 | 0 | 0 |
| Other Investing Cash Flow Items, Total | -2.79813 | 0.4516 | 0 | 0 | |
| Cash From Financing Activities | 0 | 48.3375 | 47.9744 | 10.856 | 3.675 |
| Financing Cash Flow Items | 0 | 20.681 | 20.681 | 3.675 | |
| Net Change in Cash | -5.91585 | 37.4947 | 40.2197 | 3.32 | 2.84942 |
| Capital Expenditures | -0.00385 | -0.00385 | 0 | ||
| Issuance (Retirement) of Stock, Net | 27.6565 | 27.2934 | 10.856 | ||
| Foreign Exchange Effects | -0.139 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Newman (Michael James) | Individual Investor | 16.2879 | 1368356 | 0 | 2022-08-03 | LOW |
| Anderson (Glen R) | Individual Investor | 12.9394 | 1087048 | 348956 | 2022-07-07 | MED |
| Lee (Hoonmo) | Individual Investor | 8.2671 | 694522 | 0 | 2021-09-29 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.98 | 250348 | 101 | 2022-12-31 | LOW |
| The Investment House LLC | Investment Advisor | 1.1383 | 95629 | 0 | 2022-12-31 | LOW |
| Meckler (Jeffrey A) | Individual Investor | 0.8972 | 75374 | 10000 | 2022-11-21 | LOW |
| Strategy Asset Managers, L.L.C. | Investment Advisor | 0.6587 | 55336 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6014 | 50521 | -101 | 2022-12-31 | LOW |
| Stratos Wealth Partners, Ltd. | Investment Advisor | 0.3194 | 26832 | 0 | 2022-12-31 | LOW |
| Vivaldi Capital Management, LLC | Investment Advisor/Hedge Fund | 0.2857 | 24000 | 0 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2318 | 19473 | 0 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.2274 | 19100 | -600 | 2022-12-31 | HIGH |
| Susquehanna International Group, LLP | Investment Advisor | 0.1725 | 14495 | 14495 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1141 | 9587 | 0 | 2022-12-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0803 | 6742 | 6418 | 2022-12-31 | HIGH |
| Northern Trust Global Investments | Investment Advisor | 0.0394 | 3311 | 0 | 2022-12-31 | LOW |
| Litchev (Boyan Vesselinov) | Individual Investor | 0.0137 | 1150 | 500 | 2022-12-01 | HIGH |
| Maddaluna (Anthony J) | Individual Investor | 0.008 | 670 | 0 | 2022-08-03 | LOW |
| Bangor Savings Bank | Bank and Trust | 0.0048 | 400 | 0 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 0.0043 | 365 | 0 | 2022-12-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Indaptus Therapeutics, Inc. Company profile
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc, formerly Intec Parent, Inc, offers immunotherapy to cure diseases. The Company is engaged in developing pre-clinical pipeline of therapeutic candidates to produce anti-tumor and anti-viral responses and cure diseases. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Indaptus Therapeutics Inc revenues was not reported. Net loss decreased 57% to $4.5M. Lower net loss reflects Research and development decrease of 71% to $1.6M (expense), General and administrative decrease of 40% to $2.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$14.14 to -$1.13.
Equity composition
5/2012, Rights Issue, 2 new shares for every 22 shares held @ ILS0.9 (Factor: 1.00441). 9/2014, Rights Issue, 2 new shares for every 15 shares held @ ILS0.6 (Factor: 1). 3/2015, 1-for-50 reverse stock split (Factor: 0.02). 3/2015, Nominal value changed from ILS1.
| Industry: | Biotechnology & Medical Research (NEC) |
3 Columbus Circle
15Th Floor
NEW YORK
NEW YORK 10019
US
Income Statement
- Annual
- Quarterly
News
China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023
World refined copper market in 103,000 tonne surplus in January –ICSG
March 22 (Reuters) - The world's refined copper market had a 103,000 tonne surplus in January, compared with a 10,000 tonnes surplus the previous month, the International Copper Study Group (ICSG) said in its latest monthly bulletin.
15:10, 22 March 2023
Fitness chains add financial muscle as more Americans hit the gym
By Deborah Mary Sophia
15:07, 22 March 2023
House Republicans subpoena labor authorities in Starbucks union dispute - WSJ
March 22 (Reuters) - A Congressional committee issued a subpoena to the National Labor Relations Board, alleging that employees of the labor body mishandled union elections at Starbucks Corp SBUX.O cafes in ways that favored unionizing workers, the Wall Street Journal reported on Wednesday, citing a letter.
15:06, 22 March 2023
China Evergrande publishes plan to restructure $22.7 bln offshore debt
HONG KONG, March 22 (Reuters) - China Evergrande Group 3333.HK on Wednesday published long-awaited plans to restructure its $22.7 billion of offshore debt.
15:02, 22 March 2023
Crop merchant Louis Dreyfus to step up spending after earnings boost
Writes through with details, quote
14:59, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com